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Abstract
Background: Ischemic stroke results in a robust inflammatory response within the central nervous system. As the
immune-inhibitory CD200-CD200 receptor 1 (CD200R1) signaling axis is a known regulator of immune homeostasis,
we hypothesized that it may play a role in post-stroke immune suppression after stroke.
Methods: In this study, we investigated the role of CD200R1-mediated signaling in stroke using CD200 receptor
1-deficient mice. Mice were subjected to a 60-min middle cerebral artery occlusion and evaluated at days 3 and 7,
representing the respective peak and early resolution stages of neuroinflammation in this model of ischemic stroke.
Infarct size and behavioral deficits were assessed at both time points. Central and peripheral cellular immune
responses were measured using flow cytometry. Bacterial colonization was determined in lung tissue homogenates
both after acute stroke and in an LPS model of systemic inflammation.
Results: In wild-type (WT) animals, CD200R1 was expressed on infiltrating monocytes and lymphocytes after stroke but
was absent on microglia. Early after ischemia (72 h), CD200R1-knockout (KO) mice had significantly poorer survival rates
and an enhanced susceptibility to spontaneous bacterial colonization of the respiratory tract compared to wild-type
(WT) controls, despite no difference in infarct or neurological deficits. While the CNS inflammation was resolved by day
7 post-stroke in WT mice, brain-resident microglia and monocyte activation persisted in CD200R1-KO mice,
accompanied by a delayed, augmented lymphocyte response. At this time point, CD200R1-KO mice displayed
greater weight loss, more severe neurological deficits, and impaired motor function compared to WT. Systemically,
CD200R1-KO mice exhibited signs of persistent infection including lymphopenia, T cell activation and memory
conversion, and narrowing of the TCR repertoire. These findings were confirmed in a second model of acute
neuroinflammation induced by systemic endotoxin challenge.
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Conclusion: This study defines an essential role of CD200-CD200R1 signaling in stroke. Loss of CD200R1 led
to high mortality, increased rates of post-stroke infection, and enhanced entry of peripheral leukocytes into
the brain after ischemia, with no increase in infarct size. This suggests that the loss of CD200 receptor leads
to enhanced peripheral inflammation that is triggered by brain injury.
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Background
Ischemic stroke is currently the fifth leading cause of
death and the leading cause of long-term disability in
the USA [1]. Stroke-induced inflammation is believed to
contribute to neuronal damage, injury progression, and
clinical outcome [2]. In particular, phagocytic microglia
and macrophages of the innate immune system have
been shown to play pivotal roles in the brain’s response
to injury. Microglia, the resident immune cells of the
CNS; and macrophages; and their peripheral counter-
parts primarily serve to maintain immune homeostasis
via tightly regulated pro- and anti-inflammatory signal-
ing pathways [3]. However, in a pathological setting like
ischemic stroke, this signaling can become overactive or
dysregulated, exacerbating neuronal cell death and loss
of function [4].
Among the homeostatic mechanisms that regulate the
activation state of microglia/macrophages are a group of
membrane-associated glycoproteins known as immune
inhibitory receptors, which are responsible for regulating
CNS inflammation via neuronal-glial interactions. Emer-
ging data has shown that the interaction of CD200R1, an
inhibitory immune receptor expressed on myeloid cells,
with the CD200 ligand expressed on neurons leads to
downstream inhibition of pro-inflammatory pathways,
maintaining microglia in an inactive, resting state [5, 6].
Following tissue injury, these interactions between neu-
rons and microglia are disrupted, lifting the “brake” on
inflammation and enabling a pro-inflammatory response.
While it is likely that CD200-CD200R1 signaling may be
disrupted after stroke [7–11], the functional contribution
of the CD200-CD200R1 immune-inhibitory signaling
axis in stroke is not currently known.
Interestingly, ischemic stroke results in a dual-edged
peripheral inflammatory response, characterized by an
early increase in pro-inflammatory cytokine production
followed by a state of profound immunosuppression
[12]. This results in an increased susceptibility to pul-
monary and urinary tract infections, affecting approxi-
mately 20% of all stroke patients and significantly
increasing mortality rates [13, 14]. However, the role of
immune inhibitory molecules like CD200R1 in the per-
ipheral inflammatory response and susceptibility to in-
fection after brain injury remains largely unexplored.
In this study, we investigated the role of CD200-
CD200R1 signaling on experimental stroke outcome and
post-stroke infection risk. CD200R1-knockout (KO) and
wild-type (WT) littermate control mice were subjected
to 60-min transient middle cerebral artery occlusion
(tMCAO) and evaluated up to 1 week for post-acute
changes in microglia proliferation, monocyte infiltration,
and behavioral deficits. We demonstrate that CD200R1
inhibitory signaling functions as a critical regulator of
the peripheral immune response after brain injury,
impacting survival and the susceptibility to post-stroke
infection. In light of this, the CD200R1 axis may repre-
sent a potential therapeutic target for the treatment of
ischemic stroke and other sterile brain injuries, via the
suppression of deleterious leukocyte activation and
amelioration of stroke-induced lymphopenia.
Methods
Mice/animals
CD200R1+/− mice (bred on a C57BL/6J background)
were generously provided by Professor R. Gorczynski
(Toronto, Canada) [15]. Heterozygous CD200R1+/− mice
were bred to obtain CD200R1−/− mutants and
CD200R1+/+ wild-type littermates. Young adult male
mice (12–14 weeks of age) were pair-housed on sawdust
bedding in a pathogen-free facility (light cycle 12/12 h
light/dark). All animals had access to chow and water ad
libitum.
Ischemic stroke model
Cerebral ischemia was induced by 60min of transient
MCAO under isoflurane anesthesia as previously de-
scribed [16]. Rectal temperatures were maintained at ap-
proximately 37 °C during surgery and ischemia with an
automated temperature control feedback system. Briefly,
a midline ventral neck incision was made, and unilateral
MCAO was performed by inserting a 6.0 Doccol mono-
filament (Doccol Corp, Redland, CA) into the right in-
ternal carotid artery 6 mm from the internal carotid/
pterygopalatine artery bifurcation via an external carotid
artery stump. Sham-operated animals underwent the
same surgical procedure, but the suture was not ad-
vanced into the internal carotid artery. All animals were
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randomly assigned to stroke/sham surgery, and analysis
was performed blinded to the surgical conditions.
Behavioral testing
Body weight was monitored daily. Neurological deficits
were assessed by the Bederson score system from 0 (no
deficit) to 4 (severe deficit), with minor modifications
[17]. Mice underwent a variety of behavioral testing, in-
cluding nesting activity (overnight), neurological scoring,
static rod, and rotarod. All the animals were tested on
each behavioral task 3 days prior to surgery, to establish
a baseline, and again on the day of sacrifice. All mice in-
cluded in this study did not demonstrate any behavioral
deficits at baseline. All testing was performed at a fixed
time (09:00 am–12:00 am) by an investigator blinded to
the genotype and surgical condition.
Static rod
Balance and coordination were assessed using the static
rod test, a well-validated assessment of motor balance
[18, 19]. In this test, a wooden rod of 60 cm in length
and 2.8 cm in diameter was used as previously described
[20], with minor modification. Briefly, the rod was fixed
by a G-clamp to a laboratory table such that the rod
horizontally protruded into space 60 cm above a
cotton-padded floor. Mice were placed at the free end of
a fixed horizontal rod 60 cm above a cotton-padded floor
facing away from the home table (nose tip one head’s
length from the edge) and were allowed a maximum
period of 180 s to turn 180°. The time taken to achieve
this orientation was scored for each mouse and taken as
an average of three trials. The number of falls and suc-
cessful turns was also tallied for each trial, and the per-
centage was calculated.
Rotarod
Mice were placed on a rotating cylindrical rod accelerat-
ing from 2 to 20 rpm, over a span of 5 min [21, 22]. Sub-
jects were tested over four trials at baseline and on day 7
post-stroke, with a 5-min break between trials. The la-
tency of the subject to fall from the rotating rod was re-
corded for each trial (in seconds), and the average
latency was used for further analysis. No differences
were found between groups at baseline.
Nesting activity
Two hours prior to the onset of the dark phase, mice
were separated into individual cages and supplied with a
~ 5 cm × 5 cm pressed cotton square. Nesting activity
was assessed as described previously [23, 24], with minor
modifications. In brief, after mice had habituated for 15
min in a novel empty cage, the cotton pad was weighed
and placed into a randomized cage corner. The next
morning (approximately 12 h later), the cages were
inspected for nest construction. Any loose, shredded
material was gently brushed off the intact nesting pad.
Nesting activity was calculated as follows: [1 − (post-pad
wt. (g)/pre-pad wt. (g))] × 100 = % nested material.
Terminal histopathology
All animals were sacrificed at 72 h or 7 days after stroke via
avertin overdose (i.p). For the 72-h cohorts, the brains were
collected and hardened at − 20 °C for 5min, cut into five
2-mm coronal sections, and stained with 1.5% 2,3,5-triphe-
nyltetrazolium chloride (TTC) for 8min at 37 °C. The slices
were formalin-fixed (4%) and infarct volumes analyzed
using Sigma Scan Pro software as previously described [25].
Final infarct volumes were presented as a percentage of
contralateral structures, with correction for edema. A sep-
arate cohort of animals was sacrificed at 7 days for
sub-acute infarct analysis and immunohistochemistry. After
transcardial perfusion with cold PBS followed by 4%
paraformaldehyde, the brains were removed and fixed
for 24 h in 4% paraformaldehyde (PFA) before being
placed into a cryoprotectant solution (30% sucrose).
The brains were cut into 40-μm free-floating sections
on a freezing microtome, and every eighth slice was
stained by Cresyl violet (CV) staining to evaluate ische-
mic cell damage. The images were digitalized, and cere-
bral atrophy was analyzed using computer software
(Sigma scan Pro5) as previously described [26, 27].
India ink vascular staining
WT and KO mice were anesthetized (isoflurane) and
perfused with PBS followed by 4% paraformaldehyde
and India ink (50% India ink, 5% FeSO4 in PBS). The
brains were harvested and visualized using a digital cam-
era after brief refrigeration (Pansonic HC V770).
Immunohistochemistry
Immunohistochemical staining of fixed-frozen sections
(40 μm thickness) was performed as described previously
[28]. Briefly, the brain slices were mounted onto
gelatin-coated slides, and primary antibody (rabbit
anti-Iba1, Wako, 1:250) was added overnight. Secondary
antibodies (1:1000) with corresponding conjugates and
4′,6-diamidino-2-phenylindole and dihydrochloride
(DAPI, 1:1000, Invitrogen, Carlsbad, CA) were applied.
Images were analyzed with a Zeiss Axiovert 200M micro-
scope (Carl Zeiss, Oberkochen, Germany) and ImageJ
software (NIH).
Tissue processing for flow cytometry
Mice were euthanized and transcardially perfused with
60mL cold sterile PBS, and the brains were harvested.
The blood was drawn with heparin-coated needles and
subjected to three rounds of 10 min red blood cell lysis
with Tris ammonium chloride on ice. The ipsilateral
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hemispheres were placed in complete RPMI 1640
(Lonza) medium and mechanically and enzymatically
digested in collagenase/dispase (1 mg/mL) and DNAse
(10 mg/mL; both Roche Diagnostics) for 1 h at 37 °C.
The cell suspension was filtered through a 70-μm filter
and placed into a 70%/30% Percoll gradient. Following
centrifugation, leukocytes were harvested from the inter-
phase portion of the gradient. Cells were washed and
blocked with mouse Fc Block (CD16/CD32, eBioscience)
prior to staining with primary antibody-conjugated
fluorophores (eBioscience): CD45-eF450 (clone: 30-F11),
CD11b-APCeF780 (clone: M1/70), CD3e-APC (clone:
17A2), Ly6C-PerCP-Cy5.5 (clone: HK1.4), and Ly6G-PE
(clone: 1A8). For live/dead discrimination, a fixable
viability dye, carboxylic acid succinimidyl ester (CASE-
AF350, Invitrogen), was diluted at 1:300 from a working
stock of 0.3 mg/mL. Data was acquired on a LSRII using
FACsDiva 6.0 (BD Biosciences) and analyzed using
FlowJo (Treestar Inc.). A gating strategy was designed as
previously described [29]. Resident microglia were identi-
fied as the CD45intCD11b+Ly6C− population, whereas
bone marrow-derived leukocytes were identified as
CD45hi. Cell type-matched fluorescence minus one
(FMO) controls were used to determine the positive gat-
ing for each antibody. The following antibodies were also
used in this study: CD11a-APC (clone: M17/4, Biolegend),
CD44-FITC (clone: IM7, eBioscience), CD69-APC (clone:
H1.2F3, eBioscience), CD200R1-FITC (clone: OX110,
Biolegend), CD19-AF700 (clone: 6D5, eBioscience),
MHCII-Bv510 (clone: M5/114.15.2, Biolegend), NKp46-
PerCPeF710 (clone: 29A1.4, eBioscience), and CD49b-PE
(clone: DX5, Biolegend).
TCRvβ usage
We used a mouse vβ TCR screening panel (BD Phar-
mingen) according to the manufacturer’s instructions.
Briefly, blood leukocytes from each sample were divided
into 15 separate FACS tubes and stained for the
antibody cocktail including 1 of 15 respective TCRvβ
FITC-conjugated monoclonal antibodies [30].
Phagocytosis assay
Prior to blocking, fluorescent latex beads (Fluoresbrite
Yellow Green (YG) carboxylate microspheres; 1um
diameter; Polysciences) were added to the isolated
microglia ex vivo in a final dilution of 1:100 as described
[29, 31]. After 1 h incubation at 37 °C with periodic agi-
tation, the cells were washed three times with FACS buf-
fer, resuspended in FACS buffer, stained for surface
markers, and fixed in PFA.
Intracellular cytokine production
For intracellular cytokine staining, a stock solution of bre-
feldin A (Sigma) was prepared at 20mg/mL in DMSO
and diluted with PBS to obtain a working solution of 0.5
mg/mL. Mice were euthanized 12 h after intravenous in-
jection of brefeldin A (250 μL). Leukocytes were collected
as described above, and 1 μL of GolgiPlug containing bre-
feldin A (BD Biosciences) was added to 800 μL complete
RPMI. Cells were resuspended in Fc Block, stained for
surface antigens, and washed in 100 μL of fixation/
permeabilization solution (BD Biosciences) for 20min.
Cells were then washed twice in 300 μL permeabilization/
wash buffer (BD Biosciences) and resuspended in an intra-
cellular antibody cocktail containing TNF-PE-Cy7 (clone:
MP6-XT22, eBioscience) and IL-1β-FITC (clone: NJTEN3,
eBioscience), followed by fixation.
Endotoxin challenge model
Mice were injected with lipopolysaccharide (LPS) endo-
toxin derived from Escherichia coli O114:B4 (strain
O111:B4; Sigma-Aldrich, St. Louis, MO, USA). LPS was
dissolved in phosphate-buffered saline (PBS, pH 7.4) at a
concentration of 1 mg/mL. A frozen aliquot of the LPS
was prepared in normal saline on the day of use. To gen-
erate peripheral inflammation, animals were given a sin-
gle i.p. injection of LPS at 5 mg/kg.
Sickness behavior
Sickness behavior is normally a temporary state character-
ized by adaptive behavioral- and neuroimmune-specific
changes orchestrated by the host to fight the invading
pathogens [32, 33]. Typical symptoms of sickness be-
havior are reduced posture movement (scored as fol-
lows: 0 = normal behavior, 1 = hunched but still
avoid moving, 2 = hunched and not moving), eye
squinting (a symptom of discomfort scored as follows:
0 = no eye squinting, 1 = moderate eye squinting in
both eye, 2 = severe eye squinting in both eye), hair
striking (scored as follows: 0 = normal behavior, 1 =
hair is only partially sticking up, 2 = hair sticking up
on the whole back), prostration touch response
(scored as follows: 0 = a normal mouse runs away
and tries to avoid touch, 1 = moderate response, 2 =
animal was completely unresponsive), and weight loss.
Measurement of brain cytokine and hemoglobin
concentrations
The ipsilateral brain was homogenized using a Dounce
homogenizer in ten volumes of NP40 cell lysis buffer
(FNN0021, Thermo Fisher Scientific, USA) supple-
mented with 1 mM phenylmethylsulphonyl fluoride
(PMSF) and a protease inhibitor cocktail (Sigma-Al-
drich). All steps were carried out at 4 °C. The homogen-
ate was centrifuged initially at 700×g for 5 min to
eliminate unruptured cells and debris and then further
centrifuged at 12,500g for 20 min. The supernatant was
used to measure cytokine levels by ELISA. Tumor
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necrosis factor-alpha (TNF-α) and IL-1β levels were mea-
sured by commercially available specific quantitative
multiplex ELISA kits according to the manufacturer’s in-
structions (# M60000007A, Bio-Rad Laboratories,
Hercules, CA). Hemoglobin levels were measured by com-
mercially available colorimetric determination of total
hemoglobin according to the manufacturer’s instructions
(# DIHB-250, BioAssay Systems, Hayward, CA).
Complete blood count assay
Complete blood count (CBC) was performed by
using IDEXX ProCyte Dx Hematology Analyzer ac-
cording to the manufacturer’s instructions (IDEXX,
Westbrook, Maine, USA). Briefly, approximately
300 μL of whole blood from each animal was diluted
in 100 μL of 0.5 M EDTA (Sigma), then diluted sam-
ples were placed in an automated ProCyte Dx
Hematology Analyzer.
CD200 ELISA
Protein concentrations were assayed using a mouse
CD200 PicoKine ELISA kit (Boster Bio, Pleasanton, CA).
Plasma samples and 100 μg of whole cell lysate brain
protein were plated in triplicate for each sample and
assayed according to the manufacturer’s instructions
using a microplate reader (EnSpire 2300 Multilabel
Reader, Perkin Elmer). CD200 protein concentration was
quantitatively determined by measuring the optical dens-
ity absorbance at 450 nm.
Serum LPS-binding protein assay
LPS-binding protein (LBP) in serum was measured by
commercially available specific quantitative sandwich
ELISA kits according to the manufacturer’s instructions
(# KA0449, Abnova, Walnut, CA, USA).
Lung CFU counts
After sacrifice, both the left and right lungs were har-
vested from mice under sterile conditions and main-
tained at 4 °C. Half of the tissue from both lungs was
homogenized in sterile 1× PBS, and the homogenate was
allowed to sit for 1 min at room temperature. Tenfold
serial dilutions were obtained from the lung homogen-
ate, ranging from 10−1 to 10−10. Each dilution was plated
on a blood agar plate and incubated under anoxic condi-
tions (Coy Laboratory Products) at 37 °C chamber over-
night [34, 35]. Positive colonies were recorded, and
colony-forming units (CFU) were calculated per gram of
lung tissue (wet weight).
Statistical analyses
Data from individual experiments are presented as
mean ± SEM and assessed by Student t test or one-/
two-way ANOVA with Tukey post-hoc test for multiple
comparisons and Hold-Sidak test for paired comparisons
(GraphPad Prism Software Inc., San Diego, CA, USA).
Kaplan-Meier survival curves were compared using
Cox-Mantel analysis to determine statistical significance
between the groups. A significance was set at p ≤ 0.05.
The neurological deficit scores and sickness behavioral
scores were analyzed using the Mann-Whitney U test.
Data obtained from behavioral testing and flow cytome-
try experiments are representative of two biological rep-
licates using animals from different litters. All the
studies were performed by investigators blinded to the
genotypes of the mice.
Results
CD200R1-deficient mice have higher mortality associated
with exacerbated microgliosis and monocyte infiltration
at 72 h after stroke independent of infarct volume
To begin, we examined whether CD200R1 deficiency al-
tered acute outcomes following experimental ischemic
stroke. Despite significantly higher mortality rates in
CD200R1-KO mice within the first week of injury (p <
0.05), no difference between neurological deficits scores
was found at day 3 after MCAO (Fig. 1a, b). Consistent
with this finding, infarct analysis revealed no statistical
difference between the groups (Fig. 1c, d). However,
both the central and peripheral neuroinflammatory re-
sponse was augmented in CD200R1-KO mice as mea-
sured by brain flow cytometry. Significantly greater
numbers of microglia were seen in CD200R1-KO mice
compared to WT at 72 h post-stroke, despite no differ-
ences in microglia counts at baseline (Fig. 1e, f; p ≤ 0.05).
In addition, infiltrating peripheral lymphocyte and mye-
loid cell counts were significantly higher in the
CD200R1-KO brains at 72 h compared to WT (Fig. 1g).
Further resolution of myeloid subsets revealed that
monocyte numbers were approximately four times
greater in the ischemic hemisphere of CD200R1-KO
mice compared to WT controls, with no significant dif-
ference in neutrophil counts (Fig. 1h, i; p ≤ 0.001). Fur-
ther surface phenotyping showed that the integrin
adhesion molecule CD49d is significantly upregulated on
circulating monocytes deficient for CD200R1, suggesting
that increased leukocyte-endothelial contact might
facilitate enhanced entry of monocytes into the ischemic
brain of CD200R1-KO mice (Fig. 1i–k). Next, we
examined the expression of CD200R1 protein on
brain-resident microglia and peripheral infiltrating im-
mune cells 72 h after experimental ischemic stroke.
Interestingly, the surface expression of CD200R1 protein
was nearly absent on microglia in healthy and ischemic
brains (Fig. 1l, m). Modest expression was found on
brain-infiltrating myeloid cells, and comparably higher
expression was found on the infiltrating lymphocyte popu-
lation (p ≤ 0.001). No change in CD200 concentration was
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found in the brain or plasma after stroke in WT mice
(Additional file 1: Figure S1). These findings suggest that
the increased mortality seen in CD200R1-KO mice may
be mediated by an aggravated inflammatory response in-
dependent of infarct size.
Myeloid functions are differentially affected in the
ischemic brain of CD200R1-KO mice
As our initial experiments demonstrated that CD200R1
deficiency augments myeloid infiltration into the brain,








Fig. 1 CD200R1-KO mice have greater mortality associated with exacerbated microgliosis and monocyte infiltration independent of infarct size at
72 h after ischemic stroke. A Kaplan-Meier survival curve shows the extent of mortality in each group of a cohort following 60min of MCAO (a; N= 18–21/
group). Neurological deficit scores were assessed for each group at 72 h (b; N= 18/group). Representative images of 2,3,5-triphenyltetrazolium chloride
(TTC)-stained coronal brain sections for CD200R1-knockout (KO) and CD200R1-wild-type (WT) control littermates at 72 h after 60min of middle cerebral
artery occlusion (MCAO) (c). Infarct volumes were measured for the total ipsilateral hemispheric area relative to the contralateral side (d; N= 9/group).
Representative dot plots depict the extent of CD45intCD11b+ microgliosis and CD45hiCD11b+ myeloid cell infiltration in the ischemic brain of each group
(e). The absolute number of microglia (CD45intCD11b+Ly6C−) was quantified at 72 h (f; N= 7/group). The absolute number total infiltrating myeloid cells
(CD45hiCD11b+) and putative lymphocytes (CD45hiCD11b−) was quantified (g). A dot plot shows the identification of specific myeloid subsets in the
ischemic brain (h). The number of monocytes (CD45hiCD11b+Ly6C+Ly6G−) and neutrophils (CD45hiCD11b+Ly6C+Ly6G+) was compared between
genotypes (i). The percentage of CD49d-positive monocytes in the blood and brain of stroke-injured mice is shown (j) by histogram (CD200R1-WT = blue,
CD200R1-KO = red, blood = dotted line, brain = solid line, FMO = shaded gray). Quantification of these data shows greater α4-integrin upregulation on
circulating monocytes in CD200R1-KO mice (k). Representative histograms illustrate the relative level of CD200R1 expression on CD45intCD11b+ microglia,
CD45hiCD11b+ myeloid cells, and CD45hiCD11b− lymphocytes in the brain at 72 h after stroke (l; KO = red, WT = blue). Quantification of these
data is shown (m; N = 7–15/group). Asterisks adjacent to group labels designate an effect of genotype by one-way ANOVA. FMO controls were
used to determine positive gating. Error bars show mean SEM. SH sham, ST stroke, KO knockout, WT wild-type, SEM standard error of mean.
*p < 0.05; **p < 0.01; ***p < 0.001
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myeloid cell phenotype and function. Ex vivo assays
were performed on freshly isolated leukocytes from the
ischemic brain at 72 h after MCAO. Given the import-
ance of clearing cellular debris following ischemic tissue
damage, we first evaluated the level of phagocytic activ-
ity by each myeloid subset. Our data demonstrate a sig-
nificant increase in the percentage of CD200R1-KO
monocytes with enhanced phagocytic activity compared
to their WT counterparts. No differences in microglia or
neutrophil phagocytosis were seen between the groups
(Fig. 2a, b; p ≤ 0.05). As heightened phagocytic activity is
regarded as beneficial and is generally associated with an
attenuated cytokine response, we next performed intra-
cellular staining in these cells to examine the production
of the pro-inflammatory cytokines TNF-α and IL-1β in
response to ischemic brain injury. The relative protein
expression levels of TNF-α and IL-1β were significantly
lower in CD200R1-deficient monocytes after stroke
compared to WT controls (Fig. 2c–f; p ≤ 0.01 and p ≤
0.05, respectively). Although no differences were seen in
microglia, CD200R1-deficient neutrophils expressed
lower levels of TNF-α relative to their WT counterparts
(Fig. 2d; p ≤ 0.01). Collectively, these data indicate that
monocyte function is uniquely affected by CD200R1
deletion.
CD200R1-KO mice have worse functional outcomes and
behavioral deficits at day 7 after stroke, independent of
neuronal injury
In order to test the temporal impact of CD200R1 signal-
ing, we next examined the effects of CD200R1 deficiency
on stroke outcomes at day 7 in addition to day 3. Interest-
ingly, CD200R1-KO mice displayed significantly worse
neurological deficit scores at day 7 compared to controls
(Fig. 3a; p = 0.003), a detrimental effect of CD200R1 dele-
tion not seen at day 3 (Fig. 1b). No significant difference
was seen in tissue atrophy between groups by Cresyl violet
staining (Fig. 3b, c). Notably, CD200R1-KO mice exhibited
a dramatic decrease in body weight following stroke,
nearly twice that of WTcontrols (Fig. 3d; p = 0.003), which
was accompanied by significant dysregulation in body
temperature (Fig. 3e; p ≤ 0.05). While, thymic atrophy per-
sisted to a greater degree in CD200R1-KO mice at day 7
(Fig. 3f, p ≤ 0.05), no differences in splenic atrophy were
found between the groups (Fig. 3g).
Next, to see whether these poor physiological outcomes
were associated with deficits in functional recovery, we ran
a battery of behavioral tests to measure sensorimotor defi-
cits and anxiety/depressive features after stroke. Import-
antly, no differences were seen between genotypes at




Fig. 2 Lack of CD200R1-mediated immune inhibitory signaling differentially affects myeloid cell functions in the ischemic brain. Representative
histograms illustrate the functional differences in phagocytic activity (a) and TNF-α (b) and IL-1β (c) production between infiltrating monocytes of
CD200R1-KO (red) and WT littermate controls (blue) at 72 h after ischemic stroke. Cell-specific FMO controls were used to determine positive gating
(shaded gray). Results from the ex vivo phagocytosis bead assay were quantified for resident microglia (CD45intCD11b+Ly6C−) and brain-infiltrating
monocytes (CD45hiCD11b+Ly6C+Ly6G−) and neutrophils (CD45hiCD11b+Ly6C+Ly6G+) in each group (b; N = 6/group). The mean fluorescence
intensities (MFI) of TNF-positive (d) and IL-1β-positive (f) myeloid cells were measured to assess differences in the relative protein expression level of
these subsets between groups (N = 6 mice/genotype/surgery group). Asterisks adjacent to group labels designate an effect of genotype by two-way
ANOVA. KO knockout, WT wild-type, SEM standard error of mean. *p < 0.05; **p < 0.01
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impairment in their ability to remain stable on an accelerat-
ing cylinder rod, having a shorter latency to fall (Fig. 3h,
p ≤ 0.05). Similarly, we found that CD200R1-KO mice failed
to successfully orient themselves without falling in approxi-
mately half of the trials on a static bar test (Fig. 3i, p ≤ 0.01).
Lastly, we assessed for deficits in the ability to perform nor-
mal daily activities such as nest construction. CD200R1-KO
mice showed a significant reduction in nesting activity
1 week after stroke as compared to WT controls (Fig. 3j,
p ≤ 0.05). Collectively, this data implies that immune-inhibi-
tory interactions in the CNS are not only critical for sur-
vival after stroke, but also for the recovery of motor
processes involved in balance and coordination as well as
the capacity to perform normal daily tasks.
CD200-CD200R1 signaling promotes the resolution of
leukocyte infiltration into the ischemic brain, resulting in
improved neurological recovery
Next, we examined whether the increased behavioral
deficits seen in CD200R1-KO mice at day 7 after
stroke were associated with persistent neuroinflamma-
tion. The immunohistological analysis confirmed a
significant increase in Iba1-positive microglia/
macrophages in the striatum of CD200R1-KO mice
compared to WT controls at 7 days after stroke
(Fig. 4a, b; p = 0.045). Flow cytometry analysis con-
firmed that microglia counts were significantly ele-
vated out to day 7 in CD200R1-KO mice (Fig. 4c, d;
p = 0.039). As the day 7 post-stroke period is charac-
terized by the delayed recruitment of T cells [36–39],
we hypothesized that lymphocyte numbers would be
more abundant in the brain of CD200R1-KO mice
compared to their WT counterparts. An analysis of
total CD45hi peripheral leukocyte counts found that
CD200R1-KO mice had approximately three times the
number of infiltrating cells as controls at 7 days, des-
pite having similar myeloid-to-lymphocyte ratios
(Fig. 4e; p = 0.0005, F(1, 42) = 14.12). Further analysis
revealed that Ly6C+Ly6G− monocytes made up the
majority of infiltrating myeloid cells, whereas T cells
(gated by CD3+) accounted for the majority of infil-
trating lymphocytes in CD200R1-KO mice (Fig. 4f, g,
respectively; p ≤ 0.001). Interestingly, nearly all mye-
loid and lymphocyte subsets were present in higher
numbers in CD200R1-KO mice after stroke, suggest-






Fig. 3 CD200R1-KO mice exhibit significantly worse functional outcomes at 1 week after stroke. Neurological deficit scores were assessed for each
group at 7 days (a; N = 16–20/group). Representative images of Cresyl violet-stained coronal brain sections for CD200R1-KO and WT control
littermates at 7 days after 60 min of middle cerebral artery occlusion (b). Tissue atrophy was measured for the total ipsilateral hemispheric area
relative to the contralateral side (c; N = 8/group). The percentage of body weight loss is shown (d). Core body temperatures were measured (e),
and spleen (g) and thymus (f) weights were normalized to body weight at 7 days (respectively N = 5 SH/group and N = 12–14 ST/group). The
latency to fall on an accelerated rotarod device was recorded (h). CD200R1-KO mice displayed a significantly greater percentage of falls in a 180°
turning test compared to WT controls (i). Nesting behavior was measured at day 7, and the percentages of used nest material are shown (j). For
all behavior experiments, N = 12–14 mice per group. Error bars show mean SEM. Asterisks adjacent to group labels designate an effect of stroke
by two-way ANOVA. KO knockout, WT wild-type, g grams, s seconds, BW body weight, SH sham, ST stroke, SEM standard error of mean.
*p < 0.05; **p < 0.01
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leukocyte infiltration into the ischemic brain. No dif-
ferences in gross vascular anatomy or hemorrhagic
transformation as measured by India ink staining and
hemoglobin assay, respectively, were seen between ge-
notypes (Additional file 2: Figure S2). ELISA analysis
of TNF-α and IL-1β showed significantly higher con-
centrations of these pro-inflammatory cytokines in is-
chemic brain tissue of KO mice compared to WT
controls at day 7 after stroke (Fig. 4h, i, respectively;
p < 0.001). CD200R1-positive T cells co-expressed
CD11a, CD69, and PD-1 in greater number and
higher levels compared to CD200R1-negative T cells
in the ischemic brain, suggesting that CD200R1 serves
as a useful T cell activation marker and a potential
target for CD200R1 agonist therapy (Fig. 4j–o; p =
0.0381, 0.0006, and 0.025, respectively). Together,
these findings suggest that at the level of the CNS,
CD200R1 signaling inhibits the early transmigration
and/or chronic entry of leukocytes into the ischemic
brain over time, which is required to facilitate a full
recovery.
The poorer functional outcomes in CD200R1-deficient
mice after stroke are associated with profound peripheral
immune suppression 1 week after stroke
The precipitous functional decline that occurs after
day 3 of stroke in surviving CD200R1-KO mice sug-
gests that the peripheral immune state is persistently
activated and functionally impaired. We therefore ex-
amined circulating blood leukocytes for evidence of
continued dysregulation. Consistent with the notion
of secondary bacterial infection, CD200R1-KO exhib-
ited prolonged lymphopenia at day 7 after stroke
(Fig. 5a). Complete blood count results confirmed
that the number of circulating white blood cells was
significantly lower in KO mice after stroke (Add-
itional file 3: Figure S3). Circulating CD4 T cells from
CD200R1-KO mice showed exaggerated upregulation
of the early TCR activation marker, CD69 (Fig. 5b, c).
Moreover, a significant increase in the frequency of
CD44hiCD62llo effector memory (Tem) cells was
found within the CD4 subset (Fig. 5d, e), suggesting
active memory conversion of naïve T cells following
a b c d
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Fig. 4 CD200R1-deficient mice demonstrate an inability to resolve neuroinflammation 1 week after ischemia. The inset of the diagram illustrates
the striatal region bordering the penumbral zone from which the following representative histological sections were taken (a; scale bar = 50 μm).
Sections were stained with the microglia/macrophage marker, anti-ionized calcium-binding adaptor molecule 1 (Iba1; in green), and the nuclear/DNA
marker 4′,6-diamidino-2-phenylindole (DAPI; in blue). The average number of co-labeled Iba1+ microglia/macrophages in the region of interest was
quantified for all sections (b; N = 8/group). Representative dot plots show greater numbers of CD45+CD11b+ and CD45hiCD11b− leukocytes in the
ischemic hemisphere of CD200R1-KO mice compared to WT controls at 7 days (c). The absolute number of CD45intCD11b+Ly6C− microglia (d) and
infiltrating CD45hi myeloid and lymphocyte populations (e) was quantified (N = 13/group). A more detailed phenotypic analysis was performed to
identify the specific myeloid (monocytes: CD45hiCD11b+Ly6C+Ly6G−; neutrophils: CD45hiCD11b+Ly6C+Ly6G+; other: CD45hiCD11b+Ly6C−Ly6G−) and
lymphocyte (T cells: CD45hiCD11b−CD19−CD3+; B cells: CD45hiCD11b−CD3−CD19+MHCII+; NK/T cells: CD45hiCD11b−CD19−NKp46+DX5+; other:
CD45hiCD11b−CD19−CD3−NKp46−DX5−) subsets in the ischemic brain (f and g, respectively). Brain concentrations of TNF-α and IL-1β in sham and
stroke mice are shown (f; N = 4–5/group). CD200R1-positive CD3+ T cells in the ischemic brain express a higher percentage of T cell activation markers
CD11a (j, k), CD69 (l, m), and PD-1 (n, o) compared to their CD200R1-negative counterparts (N = 12/group). FMO controls were used to determine
positive gating. Asterisks adjacent to group labels designate an effect of genotype by two-way ANOVA. Error bars show mean SEM. KO knockout, WT
wild-type, SEM standard error of mean. *p < 0.05; **p < 0.01; ***p < 0.001
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antigenic stimulation. The gross change observed in
the CD4 memory population may indicate expansion
and a subsequent narrowing of the TCR repertoire.
Indeed, subsequent studies of blood CD4 T cells in
CD200R1-KO mice showed a marked re-arrangement
in TCRvβ usage at 1 week after stroke, with signifi-
cantly higher frequency shifts in the subfamily mem-
ber’s vβ8.1 and 8.2 (Fig. 5f ).
CD200R1-deficient mice develop spontaneous bacterial
infection of the lung after stroke
Next, we wanted to examine the effects of the aug-
mented lymphopenia in CD200R1 mice on susceptibility
to post-stroke infection. Most strikingly, we observed a
52% survival rate for CD200R1-KO mice by day 7 after
stroke, significantly lower than was seen for WT controls
(83%; p = 0.049) (Fig. 1a). No difference in body weight
or body temperature was observed during the early
stages of stroke (Fig. 6a, b). However, consistent with
our earlier results, CD200R1-KO mice showed signifi-
cantly higher CFUs in lung tissue and increased serum
LBP concentrations (Fig. 6c–e). At 72 h after stroke,
37.5% of WT mice and 100% of KO mice had an infec-
tion, whereas at day 7, 20% of WT mice and 100% of
KO mice had lung infections. These findings suggest
that CD200R1 immune inhibitory signaling is important
for controlling the spread of bacterial infection in re-
sponse to ischemic stroke.
CD200R1-deficient mice exhibit greater spontaneous
bacterial colonization of the lung and enhanced sickness
behavior after LPS administration
Next, we examined whether these findings could be rep-
licated in systemic endotoxin challenge, a second model
of acute neuroinflammation. Despite no difference in
body weight loss or body temperature regulation be-
tween genotypes (Fig. 6f, g), careful examination re-
vealed increased bacterial colonization of the lung as
measured by CFU per milligram tissue and greater
serum lipopolysaccharide-binding protein (LBP) concen-
trations, indicative of bacterial translocation and spon-
taneous infection (Fig. 6h, i). Infection rates were higher
in KO mice after LPS, with 16.6% of WT mice and 100%
of KO mice showed lung infection. Three days following
LPS injection, CD200R1-KO mice exhibited more severe
sickness behaviors including higher severity scores in
postural movement, hair striking, eye squinting, and
prostration touch responses (Fig. 6j–m). These data sug-




Fig. 5 Worsened stroke outcomes in CD200R1-deficient mice are associated with profound peripheral immune suppression 1 week after
stroke. The percentage of circulating lymphocytes was significantly lower in CD200R1-knockout mice at 7 days after MCAO compared
to wild-type littermate controls (a; N = 5/group). Stroke-induced lymphopenia was associated with an increase in the percentage of
circulating CD4 T cells expressing the early T cell receptor (TCR) activation marker, CD69 (b, c), and those with effector memory
(CD44hiCD62Llo) phenotype (d, e). A mouse vβ TCR screening panel containing 15 FITC-conjugated monoclonal antibodies was used to
assess TCR vβ usage in CD4 T cells from the blood of CD200R1-deficient mice that underwent sham and stroke surgery. The mean
percentage for each of the 15 subfamilies of T cell receptor vβ is displayed (f). Significant differences were found between the groups
illustrating the narrowing of the CD4 TCR repertoire in CD200R1-knockout mice after MCAO (N = 5/group). Cell-specific FMO controls
were used to determine positive gating. Asterisks adjacent to group labels designate a significant interaction between groups by two-
way ANOVA. Error bars show mean SEM. KO knockout, WT wild-type, SH sham, ST stroke, SEM standard error of mean. *p < 0.05;
**p < 0.01; ***p < 0.001
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systemic inflammatory challenge and that CD200-
CD200R1 signaling may be an important regulator of
secondary infection control.
Discussion
In this study, we provide evidence to support the hypothesis
that CD200-CD200R1 interactions are important for (1)
the peripheral immune control of spontaneous bacterial
lung infection post-stroke and (2) downregulating neuroin-
flammatory responses via (3) attenuation of microglia pro-
liferation and (4) inhibition of monocyte and T cell entry
into the ischemic brain and (5) are critical for acute survival
and behavioral recovery after stroke. Previous work identi-
fied the CD200-CD200R1 signaling axis as a major regula-
tor of microglial homeostasis in the healthy and diseased
CNS [5, 40]. Based on this theory, neuronal-microglial in-
teractions impart a unidirectional immune-inhibitory signal
that suppresses microglia activation and contribute to the
immune-privileged status of the CNS [41]. Our work iden-
tifies a novel role for CD200R1 in regulating the systemic
response to brain injury, including the entry and function
of bone marrow-derived monocytes and T cells within the
injured CNS. We show for the first time that CD200R1 in-
hibitory signaling is critical for preventing spontaneous lung
infection, attenuating brain inflammation, improving sur-
vival, and promoting functional recovery after stroke. These
findings implicate the CD200-CD200R1 immunoregulatory
pathway as a novel and powerful therapeutic target in is-
chemic brain injury.
Mounting evidence highlights the detrimental impact of
chronic inflammation on neuroplasticity and long-term
recovery following stroke [42]. In this study, we hypothe-
sized that neuroinflammation would be sustained in the
absence of CD200R1 inhibitory signaling. Surprisingly,
lymphocytes were found to be predominant cell type ex-
pressing CD200R1 in the ischemic brain, not microglia,
and CD200R1-positive T cells exhibited a higher level of
activation than T cells from CD200R1-deficient mice.
Mice with higher myeloid-to-lymphocyte ratios in the is-
chemic brain at 7 days had worse neurological outcomes,
potentially implying that enhanced delayed recruitment of
lymphocytes and/or augmented resolution of myeloid
a b c d
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Fig. 6 CD200R1-deficient mice exhibit greater spontaneous bacterial colonization of the lung after stroke and enhanced sickness behavior in a
LPS model of systemic immune challenge. CD200R1-mediated susceptibility to spontaneous bacterial infection was addressed after MCAO and in
a second model of LPS-induced systemic immune challenge. The percentage of body weight loss (a) and core body temperature (b) is shown at
day 3 after stroke is shown (N = 9/group). Representative images of bacterial colonies grown from lung homogenates on blood agar plates
following acute stroke are shown (c). Lung colony-forming units (CFU) counts were statistically higher at days 3 and 7 in injured CD200R1-KO
mice compared to CD200R1-WT control littermates (d). Serum concentrations of lipopolysaccharide-binding protein (LBP) at day 3 after stroke are
shown (e). Percentage body weight loss (f) and body temperature (g) were quantified at day 3 after i.p. LPS injection (N = 6/group). Bacterial
colonies cultured on blood agar demonstrated statistically higher lung colony-forming units (CFU) counts in injured CD200R1-KO mice compared
to CD200R1-WT control littermates after endotoxin challenge (h; N = 6/group). Serum concentrations of lipopolysaccharide-binding protein (LBP)
at day 3 after stroke are shown (i). Sickness behaviors were examined in CD200R1-knockout (KO) and wild-type (WT) control littermates 3 days
after systemic LPS administration. CD200R1-KO mice had significantly worse sickness scores for postural movement (j), hair striking (k), eye
squinting (l), and prostration touch response (m). For all behavioral experiments, N = 6/group. Error bars show mean SEM. SH sham, ST
stroke, KO knockout, WT wild-type, SEM standard error of mean. *p < 0.05; **p < 0.01; ***p < 0.001
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inflammation facilitates post-stroke recovery. Previous
work has shown that CD200R1 activation suppresses
macrophage migration in part by downregulating expres-
sion of the integrin adhesion molecules CD11a and
CD49d [8]. This is consistent with our finding that CD49d
is upregulated on circulating CD200R1-deficient mono-
cytes and with earlier studies that have shown increased
macrophage numbers in both sterile and autoimmune
models of brain injury in CD200-deficient mice. Previous
studies have also demonstrated that CD200-KO mice, the
ligand for CD200R, show increased blood-brain barrier
permeability, greater leukocyte infiltration, and higher
pro-inflammatory cytokine levels after LPS administration
compared to WT littermate controls [40]. These results
suggest that CD200R1 signaling is a powerful regulator of
myeloid cell function under sterile inflammatory condi-
tions both at the vascular level (i.e., facilitating entry) and
within the injured brain (i.e., modulating function).
To our knowledge, this is the first study to investigate the
functional effect of loss of CD200R1 immune-inhibitory
signaling in the CNS. The CD200 receptor family has sev-
eral isoforms, in which all but one (CD200R1) are activating
receptors that lack inhibitory motif-bearing proteins. There
is an advantage of using transgenic mice containing a gen-
etic deletion of CD200R1 rather than CD200. Any observed
effect is a result of the absence of inhibitory signaling rather
than a combination of activating and inhibitory functions
[43, 44]. The phenotypic similarities in the neuroinflamma-
tory state between CD200- and CD200R1-KO mice imply
that the combined functional role of the immune-activating
CD200R family members may be negligible [40, 44]. None-
theless, the potential for CD200 binding to induce both
activatory (i.e., CD200R2, CD200R3, CD200R4) and inhibi-
tory (i.e., CD200R1) signaling make matters complicated
when trying to determine which pathways are responsible
for the phenotype. The off-target effects of CD200R2/3/4
signaling cannot be ruled out when targeting CD200 using
genetic knockout, knockdown, Fc drug, or antibody block-
ade. Genetic deletion of CD200R1, however, selectively
removes the inhibitory pathway but leaves the activatory
pathways intact. We did not observe CD200R3 expression
on adult microglia (not shown); however, its expression
after stroke and that of the other activating family members
deserves further study. Importantly, given its unique
expression on activated or mature tissue-resident myeloid
cells and lymphocytes, previous reports indicate no obvious
signs of developmental alteration in immune homeostasis,
indicating that any limitations due to constitutive loss of
CD200R1 during development are minimal [15, 45].
Given the lack of CD200R1 expression on microglia be-
fore and after stroke, it is likely that the KO response to
injury is primarily mediated by peripheral immune cells.
The fact that CD200R1-KO mice exhibit a dramatic sus-
ceptibility to infection, only after injury or LPS, highlights
the often overlooked importance of these immune signal-
ing pathways in quelling endogenous/exogenous bacterial
invasion triggered by brain injury. While it may be coun-
terintuitive to think that increasing the activation level of
immune cells (i.e., CD200R1 KO) is detrimental to con-
trolling infection, our results support the conclusion that
interfering with the normal balance of activatory versus
inhibitory signaling causes a lack of control of the immune
response. The uncalibrated immune response and mortal-
ity that follows underscore the importance of peripheral
immune inhibitory signaling in fighting infection. Al-
though this mechanism is not well understood, it is not
without precedent. Rygiel and colleagues elegantly showed
that CD200 deficiency enhances pathological T cell re-
sponses during influenza infection [46]. CD200-KO mice
developed more severe disease and greater lung infiltra-
tion, which were completely prevented by depletion of T
cells before infection. The peripheral changes in T cell
function noted in our study are dramatic, and the high
level of CD200R1 expression on these cells, specifically
TCR-activated subsets, strongly implicates them in the de-
velopment of stroke-induced lung infection. The earlier
proposed role of hyperactivated microglia might be sec-
ondary to the pathological T cell activation [5, 47]. Differ-
ences in activation of CD200R1-deficient dendritic cells
could also account for these changes.
Recently it was shown that ICV injection of exogenous
recombinant CD200 protein at the time of permanent
MCAO reduced the expressions of Iba-1, IL-1β, TNF-α,
and IL-10 at 48 h after ischemia [48]. The authors re-
ported a negative correlation between decreasing CD200
levels after injury and increasing neuronal death. While
this study highlights the therapeutic potential of this path-
way in stroke, it did not assess functional outcomes. Our
data indicates CD200-CD200R1-mediated regulation of
immunity is essential for survival and improved behavioral
outcome following stroke. Acute mortality rates from
stroke are high, as the majority of severe stroke patients
die within the first week of hospitalization [49]. Mirroring
the clinical scenario, nearly half of the mice lacking
CD200R1 did not survive the first week following a mod-
erate ischemic brain injury, despite no difference in infarct
size between the groups. While survivor bias may partially
explain the lack of difference in neuronal injury, it does
not explain why inflammation was exacerbated and behav-
ioral deficits were worsened. Although behavioral testing
was not performed at day 3 to prevent further stress and
mortality in the KO group, it is possible that stroke-in-
duced motor impairment occurs much earlier than day 7
in these mice. Our data, however, also suggests a signifi-
cant role for CD200R1 signaling in the peripheral immune
compartment following stroke. Infectious complications,
such as post-stroke sepsis and pneumonia, tend to occur
within the first week post-stroke and are strong
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independent risk factors of death [50]. In these experi-
ments, CD200R1-KO mice exhibited progressive weight
loss, body temperature dysregulation, peripheral immune
dysfunction, and bacterial lung colonization indicative of
systemic infection. Indeed, KO mice demonstrated severe
and persistent T cell lymphopenia after stroke. Others
have also reported that LPS-induced mortality is higher in
CD200R1-KO mice versus WT, consistent with our find-
ings [51]. Given the role of CD200R1 in regulating T cell
tolerance and systemic immune function, it is possible
that CD200R1-KO mice are unable to mount the appro-
priate adaptive responses to mitigate the detrimental ef-
fects of spontaneous bacterial infections that are known to
occur in the MCAO model [14, 52, 53]. Within the
lymphocyte lineage, CD200R1 is primarily expressed on
activated memory T and B cells [45], indicating that it
may play a critical role in the adaptive immune response
to stroke. Indeed, previous work has shown that CD200−/−
mice show increased numbers of activated leukocytes and
pro-inflammatory cytokines and higher mortality in re-
sponse to experimental septicemia [54]. Surprisingly, the
authors found that CD200 deficiency did not affect bacter-
ial clearance. Differences in injury models and pathology
likely account for these discrepant findings. Interestingly,
previous work has shown that mice lacking CD200 display
an enhanced sensitivity to influenza infection, leading to
delayed resolution of inflammation and death [55]. These
findings are in line with our own and indicate that defects
in immune inhibitory signaling in the systemic immune
environment (i.e., sepsis) may serve as a critical driver of
stroke-related mortality. Interestingly, selective expansion
of memory CD4 T cells expressing TCRvβ 8.1/8.2 was
found in KO mice after stroke. This subset of murine vβ8+
T cells recognizes the superantigen staphylococcal entero-
toxin B, a virulent determinant in Staphylococcus aureus
septicemia [56]. Thus, therapeutic targeting of immune in-
hibitory axes such as the CD200R1 pathway may prove
beneficial in reducing secondary infectious complications
in already immunocompromised individuals after stroke.
Past studies have shown ample evidence for a protective
role of bone marrow-derived monocytes at acute time
points following stroke [57]. These studies highlight the
beneficial functions of this early wave of infiltrating mono-
cytes in eliminating necrotic cells, maintaining vascular sta-
bility, and inducing M2 polarization in microglia [58]. The
role of monocytes in the post-acute or chronic phase of is-
chemic brain injury is less certain, as any restoration to nor-
mal CNS homeostasis likely requires the expedient removal
of all non-resident immune cells from the brain. Our find-
ings that CD200R1-KO mice exhibit greater microglia/
monocyte numbers, but similar neurological outcomes, at
3 days indicates that the quality of inflammation may out-
weigh the quantity. Indeed, CD200R1-deficient monocytes
from the ischemic brains exhibited greater phagocytic
activity and diminished expression of pro-inflammatory cy-
tokines compared to the WT counterparts, suggesting an
important role for CD200 in monocyte/macrophage prim-
ing and/or polarization in response to ischemic stimuli.
However paradoxical, these data are consistent with those
reported from mice deficient for CX3CR1−/−, an immune
regulatory receptor similarly important for maintaining
CNS homeostasis, which demonstrates an early protective
neuroinflammatory environment after ischemic stroke [59,
60]. Despite this early beneficial phenotype, the inability to
properly polarize and clear these cells from the ischemic
brain over time appears to have detrimental consequences
for survival and neurologic recovery. The functional effect
of CD200R1 deletion on monocyte activity appears to be
cell-intrinsic rather than secondary to direct neuronal in-
jury. These data strongly implicate infiltrating monocytes as
the primary myeloid cells inhibited by the CD200R1 path-
way following acute stroke. Furthermore, the worsened be-
havioral deficits of CD200R1-KO mice appear to be
largely driven by the significant increase in delayed CNS
monocyte and lymphocyte infiltration, defining a new role
for CD200R1 in modulating the migratory activity of
peripherally derived leukocytes after injury. Taken to-
gether with the dramatically higher levels of
pro-inflammatory cytokines found in KO brains at
day 7, these data suggest that CD200R1 is required
for resolving neuroinflammation following ischemia.
The expression pattern of CD200 and CD200R1 is
relevant to its reported role as a homeostatic regulator
in the brain and forms the basis of the theory that
neuronal-glial interactions are critical for maintaining
microglial quiescence [5, 47, 61]. The developmental ex-
pression pattern of CD200 in the healthy brain has been
examined in detail [62]. CD200 is expressed in cortical
neurons throughout life, in astrocytes during early devel-
opment, and in endothelial cells during adulthood. Lu-
minal expression of CD200 has been reported by others
and suggested to be involved in the suppression of
monocyte adhesion to the brain endothelium [63]. Tem-
poral and regional changes in CD200 gene and protein
expression have also been described in rodents after
stroke. CD200 mRNA levels were lower in the ischemic
core during the first week after stroke [11]. In a separate
study, modest but significant reductions in CD200 pro-
tein expression were found in the ischemic hemisphere
during the first 48 h [48]. Our study examined CD200
protein levels in the ipsilateral hemisphere at 72 h but did
not see any change. This may be explained by previous
work which shows CD200 gene expression is dependent
on the region of the sampled ischemic brain tissue, with
greater transcription occurring in the infarct core from 1
to 2 days and subsequently lower transcription levels from
3 to 5 days relative to peri-infarct and contralateral regions
[64]. Interestingly, Masocha showed that gene expression
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was significantly increased in the brain at 4 h after sys-
temic administration of LPS, returned to baseline by 24 h,
but were dramatically lower at 1 year [65]. The long-term
impact of stroke on CD200 expression and its contribu-
tion to chronic neurodegeneration remains to be seen.
Our study has identified activated peripheral immune cells
as the predominant CD200R1 expressers in stroke, provid-
ing new cellular targets for systemically administered
CD200 supplementation therapies.
To date, our knowledge of the CD200-CD200R1 sig-
naling axis in stroke patients is in its infancy. It is not
yet known whether CD200R1-KO mice exhibit a thresh-
old effect to ischemic brain injury, as a shorter occlusion
time (e.g., 30 min) resulting in smaller infarct volumes,
and less inflammatory stimuli were not evaluated in this
study. As stroke is a disease that primarily affects the
elderly, future studies will be needed to assess the out-
comes in aged knockout mice. In addition, the require-
ment for immune inhibition may be greater with
increasing injury and in the context of chronic inflam-
mation, certain contexts such as chronic inflammation.
Future studies measuring soluble CD200 levels in the
plasma of stroke patients could determine whether this
molecule serves as a potential biomarker of neuronal in-
jury or, perhaps, could be used to identify patients at risk
for systemic immune suppression and subsequent infec-
tions, opening new doors to CD200R1 therapies.
Conclusion
By using CD200R1-deficient mice, we demonstrate that
immune inhibitory signaling is essential for survival fol-
lowing moderate-to-severe stroke. CD200R1 contrib-
utes to the resolution of neuroinflammation, uniquely
impacts monocyte responses, and is an important regu-
lator of the body’s peripheral immune response to bac-
terial infection. Our observations provide new insights
into the contribution of the CD200-CD200R1 inhibi-
tory pathway to the progression of neuroimmune dys-
function following stroke and highlight a novel role for
CD200R1 for the prevention of systemic immunosup-
pression and secondary infection after stroke. Inhibitory
receptors such as CD200R1 evolved as a strategy to
prevent autoimmunity and prolonged inflammation in
immune-privileged regions like the CNS. The compen-
satory increase in inhibitory receptor expression on the
surface of acutely and chronically activated immune
cells implies that this system can be exploited to ameli-
orate post-stroke inflammation and restore CNS
homeostasis. These findings suggest that targeting the
CD200-CD200R1 signaling axis may hold therapeutic
potential for the prevention of acute infection and the
treatment of chronic brain inflammation following
stroke.
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Additional file 1: Figure S1. CD200 protein concentrations in the
ischemic hemisphere and plasma 72 h after stroke. ELISA measurement of
CD200 protein concentrations in the ischemic brain (a) and plasma (b)
72 h after stroke shows no significant change in wild-type mice (N = 5–8/
group). Error bars show mean SEM. Abbreviations: SH sham, ST stroke,
SEM standard error of mean. (PDF 37 kb)
Additional file 2: Figure S2. No differences in gross vascular anatomy
or in hemorrhagic transformation between WT and KO mice 7 days after
stroke. Representative images of India ink-stained brains show no overt
difference in large vessel anatomy between genotypes under normal
conditions (a; ventral view). Hemoglobin concentrations in the brain 7
days after stroke show no difference in hemorrhagic transformation
between genotypes (b; N= 5/group). Error bars show mean SEM. Abbrevia-
tions: WT wild-type, KO knockout, SEM standard error of mean. (PDF 55 kb)
Additional file 3: Figure S3. Complete blood counts demonstrate
significant leukopenia in KO mice 7 days after stroke. Blood leukocyte
counts show similar values between genotypes after sham surgery.
Leukopenia and lymphopenia are exacerbated in KO, but not WT mice, 7
days after stroke (N = 4–5/group). Error bars show mean SEM. Abbreviations:
SH sham, ST stroke, WT wild-type, KO knockout, SEM standard error of mean.
(PFD 96 kb)
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